Hearts & Minds Blog

Getting to the Heart of the Matter for American Heart Month

Mary McGowan

Chief Medical Officer

American Heart Month is a timely reminder that more still needs to be done for people at risk for cardiovascular disease. As a lipid specialist, patients are frequently referred to me by their primary care physician because they are struggling to manage their patients’ elevated levels of low-density lipoprotein cholesterol (LDL-cholesterol), or “bad” cholesterol. Often this occurs because – although statins continue to be the backbone of lipid lowering therapy – not all patients, including many of my own, are able to tolerate the required… more

Cost-Effective Innovation

Tim Mayleben

President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices.  The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious.  But these drugs are priced at more than $14,000 per year, and will be used by patients for the rest of their lives.  For someone who starts taking these drugs in their 50s, the lifetime cost… more

What’s Your “Why”?

Tim Mayleben

President and Chief Executive Officer

This past weekend Esperion participated, for the 15th year, in the American Heart Association’s (AHA) annual Heart Walk to raise money for cardiovascular disease research. It is hard for me to put into words the inspiring nature of these events – as patients, survivors, doctors and others join together to combat what continues to be the leading cause of death in the U.S. This year’s AHA theme is “Why?” – fitting as of late I’ve been reflecting on my personal “why.” That is, why devote… more

AHA 2014 Scientific Sessions: IMPROVE-IT Results Reported and What They Mean for the Future of ETC-1002

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Tim Mayleben

President and Chief Executive Officer

Last month, the American Heart Association (AHA) held its annual Scientific Sessions in Chicago, IL where presenters and attendees gathered from more than 105 countries to present cutting edge breakthroughs in cardiovascular science and research.  Esperion colleagues have attended and participated in Scientific Sessions for many years and always look forward to seeing and hearing first-hand the breaking news from presenters with the same focus that we have – to reduce cardiovascular disease risk and improve the lives of people around the world. This year’s… more

Equity Financing Now Complete: Moving ETC-1002 into Phase 3

Tim Mayleben

President and Chief Executive Officer

October was a very big month for our company!  Esperion not only announced positive top-line results from the ETC-1002-008 Phase 2b study in patients with hypercholesterolemia with or without statin intolerance, but within two weeks of this announcement we completed a successful follow-on public offering raising almost $100 million.  October proved to be an exciting, very rewarding and productive month for our team and investors! Early October saw the return of exceptionally volatile stock market conditions, which made it an extremely challenging time for Esperion… more